Gemcitabine is a type of chemotherapy drug. It's used to treat certain types of cancer, like pancreatic cancer or lung cancer. It works by stopping the growth of cancer cells.
Every report comes from a Lived member, sent anonymously.
Have you tried Gemcitabine for Pancreatic Cancer?
Gemcitabine is a chemotherapy medicine, usually given into a vein (intravenously, or IV), that treats several solid cancers. In the US it is approved for pancreatic cancer that cannot be removed with surgery or has spread, where it can be used on its own; for non-small cell lung cancer that is inoperable or has spread, together with cisplatin; for metastatic breast cancer after earlier chemotherapy, together with paclitaxel; and for advanced ovarian cancer that has come back at least 6 months after platinum-based chemotherapy, together with carboplatin. It is also part of other standard combinations. For metastatic pancreatic cancer it is often paired with nab-paclitaxel (Abraxane), and for advanced biliary tract cancer (cancer of the bile ducts or gallbladder) it is given with cisplatin and the immunotherapy durvalumab (Imfinzi). Cancer specialists also use it for bladder cancer. Gemcitabine was first sold as Gemzar, a brand that has since been discontinued in the US. Most people now receive a generic version or a ready-to-use solution such as Avgemsi. A separate product, Inlexzo, is a small device placed in the bladder that slowly releases gemcitabine onto the bladder lining. It is approved for adults with bladder cancer that has not grown into the bladder muscle, includes carcinoma in situ (a flat, high-grade cancer of the bladder lining) and no longer responds to BCG (bacillus Calmette-Guérin), the standard immune treatment placed into the bladder. Because Inlexzo acts mostly inside the bladder, its experience and side effects differ from IV gemcitabine, which most of this page describes.
Cancer cells divide often, and every division requires the cell to copy its DNA. Gemcitabine is an antimetabolite, a drug that closely resembles one of DNA's natural building blocks. Inside the cell it is converted into active forms that work in two ways. One blocks an enzyme the cell needs to make fresh DNA building blocks. The other is built into the growing DNA strand in place of the real component, which halts the copying and pushes the cell into a self-destruct process. Because it acts on any cell that is copying its DNA, gemcitabine also affects healthy cells that divide quickly, especially in the bone marrow, where blood cells are made. That is why lower blood counts are its most important side effect, and why they become more likely when gemcitabine is combined with other chemotherapy.
IV gemcitabine is given by a nurse at an infusion center or hospital, as a drip into a vein that usually lasts about 30 minutes. It is given in cycles: treatment days followed by a rest. Common schedules are days 1 and 8 of a 3-week cycle, or days 1, 8 and 15 of a 4-week cycle. When used alone for pancreatic cancer, it may be given weekly for several weeks before a week off. Partner drugs such as cisplatin, carboplatin or paclitaxel are typically given on the first day of each cycle. The dose is calculated from body size, and a blood count is checked before each dose. If counts are too low, the dose may be reduced or that treatment day postponed. This is a routine safety step, not a sign that treatment has failed. The short infusion time and the no-more-than-weekly schedule also matter for safety: in studies, longer infusions or more frequent doses caused more severe side effects, including low blood pressure, low blood counts and flu-like illness. Inlexzo is inserted into the bladder by a trained clinician through a thin tube (catheter). It stays in place for 3 weeks and is then removed. A new one is inserted every 3 weeks for the first 6 months, then every 12 weeks for up to 18 more months, as long as the cancer stays controlled and side effects are manageable.
Nausea, sometimes with vomiting, is the most common complaint with IV gemcitabine. Fever and flu-like aches, a rash, swelling of the ankles or legs, mouth sores and tiredness are also common. Hair loss and tingling in the hands or feet can occur, particularly with combination regimens. Routine blood and urine tests often show mild rises in liver enzymes or small amounts of blood or protein in the urine, which the team tracks. The most important effect is on blood counts. Low white blood cells make infections more likely and more dangerous, low platelets cause easy bruising or bleeding, and low red blood cells (anemia) add to tiredness and breathlessness. During treatment, a temperature of 100.5°F (38°C) or higher, chills or other signs of infection should be reported to the care team right away, day or night, because infections during chemotherapy can become serious quickly. Check with the team before taking a medicine to bring a fever down, since it can hide that warning sign. Less common but serious problems also need a prompt call to the care team. New or worsening shortness of breath, cough or wheezing can signal lung inflammation, which can appear during treatment or up to 2 weeks after the last dose. Unusual bleeding or black stools, passing much less urine or new swelling can point to bleeding or kidney problems, including hemolytic uremic syndrome, a rare condition in which damaged blood cells clog small blood vessels in the kidneys. Yellowing of the skin or eyes or dark urine can signal liver injury, and blistering or peeling skin can signal a severe skin reaction. Severe trouble breathing, or a seizure, especially with headache, confusion or vision changes, needs emergency care. With Inlexzo, side effects are mostly in the bladder: needing to urinate often or urgently, pain or burning when urinating, blood in the urine and urinary tract infections.
Gemcitabine is not given to anyone who has had a serious allergic reaction to it. Before treatment starts, the care team checks kidney and liver function and repeats these tests along the way. Liver problems are more likely in people whose cancer has spread to the liver or who have a history of hepatitis, heavy alcohol use or cirrhosis, so these are worth raising early. Combining gemcitabine with other chemotherapy raises the chance of low blood counts, and each partner drug brings its own side effects, so the team should know every medicine and supplement being taken. Timing with radiation matters. Given at the same time as radiation, or within 7 days of it, gemcitabine can cause severe and sometimes life-threatening inflammation of the treated tissues, such as the esophagus and lungs. Every specialist involved should know about any planned or recent radiation. Gemcitabine can also cause radiation recall, a flare of inflammation in an area that was treated with radiation in the past. Gemcitabine can harm a developing baby. Women who could become pregnant are usually tested before starting and should use effective contraception during treatment and for 6 months after the last dose. Men with partners who could become pregnant should use contraception during treatment and for 3 months afterward. Breastfeeding should stop during treatment and for at least 1 week after the last dose. Gemcitabine may also reduce fertility in men, which is worth discussing before treatment begins. Inlexzo is not placed if the bladder wall is perforated or damaged, because gemcitabine could then reach the bloodstream. For people who are candidates for bladder removal (cystectomy), choosing Inlexzo first carries a real trade-off: if the cancer persists, delaying surgery can allow it to become invasive or spread. The device can be scanned with MRI only under specific conditions, so anyone ordering a scan should know it is in place.
IV gemcitabine is an outpatient treatment for most people, who go home after each infusion. Each treatment day usually includes a blood test before the drip. Delays and dose reductions because of low blood counts are common and expected, and the overall plan often continues once counts recover. What gemcitabine can achieve depends on the type and stage of cancer and the drugs it is combined with. For cancer that has spread, the aim is usually to shrink tumors, slow growth and ease symptoms rather than to cure. Imaging scans at intervals show whether it is working, and treatment generally continues while it is helping and side effects remain manageable. If the cancer grows despite treatment or side effects become too heavy, the team will discuss other options. With Inlexzo, the urology team checks the bladder at regular intervals to see whether the cancer has cleared or come back, and bladder removal remains an option if it has not.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Gemcitabine, what you've noticed, or ask the community a question.